Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note published on Sunday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

Shares of OGEN opened at $0.29 on Friday. The firm has a market cap of $3.54 million, a PE ratio of -0.04 and a beta of 0.38. The firm’s 50 day moving average price is $0.33 and its 200 day moving average price is $0.49. Oragenics has a twelve month low of $0.25 and a twelve month high of $3.89.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.